Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


21.01.2019

1 BJU Int
3 BMC Cancer
1 Endocrinology
8 Eur Urol
1 Int J Radiat Oncol Biol Phys
7 J Urol
1 Magn Reson Imaging
1 Nat Rev Urol
1 Oncogene
3 Oncology (Williston Park)
1 PLoS Genet
1 Proc Natl Acad Sci U S A
1 Prog Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. ROBINSON D, Garmo H, Van Hemelrijck M, Damber JE, et al
    Androgen deprivation therapy for prostate cancer and risk of dementia.
    BJU Int. 2019 Jan 13. doi: 10.1111/bju.14666.
    PubMed     Text format     Abstract available


    BMC Cancer

  2. BOEGEMANN M, Khaksar S, Bera G, Birtle A, et al
    Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
    BMC Cancer. 2019;19:60.
    PubMed     Text format     Abstract available

  3. ALIBHAI SMH, Ritvo P, Santa Mina D, Sabiston C, et al
    Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT.
    BMC Cancer. 2018;18:1031.
    PubMed     Text format     Abstract available

  4. RICHARDSON M, Sidhom M, Gallagher S, Grand M, et al
    PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol.
    BMC Cancer. 2018;18:588.
    PubMed     Text format     Abstract available


    Endocrinology

  5. TAKAYAMA KI, Suzuki Y, Yamamoto S, Obinata D, et al
    Integrative genomic analysis of OCT1 reveals coordinated regulation of androgen receptor in advanced prostate cancer.
    Endocrinology. 2019 Jan 11. pii: 5286515. doi: 10.1210/en.2018-00923.
    PubMed     Text format     Abstract available


    Eur Urol

  6. GORIN MA, Walsh PC
    Magnetic Resonance Imaging Prior to First Prostate Biopsy-Are we there yet?
    Eur Urol. 2018;74:409-410.
    PubMed     Text format    

  7. OST P
    It Ain't Over Till the Fat Lady Sings: The POPSTAR Trial.
    Eur Urol. 2018;74:463-464.
    PubMed     Text format    

  8. SHAH TT, Peters M, Eldred-Evans D, Miah S, et al
    Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.
    Eur Urol. 2019 Jan 8. pii: S0302-2838(18)31036.
    PubMed     Text format     Abstract available

  9. VANDEKERKHOVE G, Struss WJ, Annala M, Kallio HML, et al
    Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31050.
    PubMed     Text format     Abstract available

  10. KENFIELD SA, Van Blarigan EL, Ameli N, Lavaki E, et al
    Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer.
    Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31048.
    PubMed     Text format     Abstract available

  11. SOORIAKUMARAN P, Pavan N, Wiklund PN, Roach M 3rd, et al
    Surgery Versus Radiation for High-risk Prostate Cancer: The Fight Continues. But Is It Time To Call a Draw and Reach Consensus?
    Eur Urol. 2019 Jan 10. pii: S0302-2838(18)31040.
    PubMed     Text format    

  12. CARNEIRO B, Dizon DS
    Prostate Cancer Social Media: In YouTube We Trust?
    Eur Urol. 2019 Jan 10. pii: S0302-2838(19)30005.
    PubMed     Text format    

  13. ZLOTTA AR, Kuk C
    Further Evidence of Differences in Prostate Cancer Biomarkers Between Caucasian and Asian Men.
    Eur Urol. 2019 Jan 11. pii: S0302-2838(18)31046.
    PubMed     Text format    


    Int J Radiat Oncol Biol Phys

  14. MITIN T, Nguyen PL
    Postoperative Radiation Therapy in Localized Prostate Cancer: When, How Much, and How Fast?
    Int J Radiat Oncol Biol Phys. 2019;103:289-292.
    PubMed     Text format    


    J Urol

  15. TANEJA SS
    Re: Study of Testosterone-Guided Androgen Deprivation Therapy in Management of Prostate Cancer.
    J Urol. 2017;197:398-399.
    PubMed     Text format    

  16. FRIEDLANDER DF, von Landenberg N, Loppenberg B, Noldus J, et al
    Facility-Level Variation In Rates Of Definitive Therapy For Low-Risk Prostate Cancer Among Men With Limited Life Expectancy: An Opportunity For Value-Based Care Redesign.
    J Urol. 2018 Dec 24. doi: 10.1097/JU.0000000000000006.
    PubMed     Text format     Abstract available

  17. SIEGEL C
    Re: Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer.
    J Urol. 2019;201:208.
    PubMed     Text format    

  18. TANEJA SS
    Re: Histologic Findings Associated with False Positive Multiparametric Magnetic Resonance Imaging Performed for Prostate Cancer Detection.
    J Urol. 2019;201:227-228.
    PubMed     Text format    

  19. TANEJA SS
    Re: Role of the 4Kscore Test as a Predictor of Reclassification in Prostate Cancer Active Surveillance.
    J Urol. 2019;201:228.
    PubMed     Text format    

  20. ATALA A
    Re: A Somatically Acquired Enhancer of the Androgen Receptor is a Noncoding Driver in Advanced Prostate Cancer.
    J Urol. 2019;201:230.
    PubMed     Text format    

  21. ATALA A
    Re: TRAF4-Mediated Ubiquitination of NGF Receptor TrkA Regulates Prostate Cancer Metastasis.
    J Urol. 2019;201:230.
    PubMed     Text format    


    Magn Reson Imaging

  22. KARGAR S, Borisch EA, Froemming AT, Kawashima A, et al
    Robust and efficient pharmacokinetic parameter non-linear least squares estimation for dynamic contrast enhanced MRI of the prostate.
    Magn Reson Imaging. 2017 Dec 23. pii: S0730-725X(17)30297.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  23. VAN LEEUWEN FWB, Winter A, van Der Poel HG, Eiber M, et al
    Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer.
    Nat Rev Urol. 2019 Jan 15. pii: 10.1038/s41585-018-0140.
    PubMed     Text format     Abstract available


    Oncogene

  24. JANG D, Kwon H, Choi M, Lee J, et al
    Sumoylation of Flotillin-1 promotes EMT in metastatic prostate cancer by suppressing Snail degradation.
    Oncogene. 2019 Jan 10. pii: 10.1038/s41388-018-0641.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  25. KITTAI AS, Blank J, Graff JN
    Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Oncology (Williston Park). 2018;32.
    PubMed     Text format     Abstract available

  26. BERNARD B, Flaig TW
    POINT-Prostate Cancer Genomic Analysis: Routine or Research Only?
    Oncology (Williston Park). 2018;32.
    PubMed     Text format    

  27. KELLY WK, Knudsen KE
    COUNTERPOINT-Prostate Cancer Genomic Analysis: Routine or Research Only?
    Oncology (Williston Park). 2018;32.
    PubMed     Text format    


    PLoS Genet

  28. WANG X, Dong B, Zhang K, Ji Z, et al
    E-cadherin bridges cell polarity and spindle orientation to ensure prostate epithelial integrity and prevent carcinogenesis in vivo.
    PLoS Genet. 2018;14:e1007609.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  29. FONG LY, Jing R, Smalley KJ, Wang ZX, et al
    Human-like hyperplastic prostate with low ZIP1 induced solely by Zn deficiency in rats.
    Proc Natl Acad Sci U S A. 2018;115:E11091-E11100.
    PubMed     Text format     Abstract available


    Prog Urol

  30. DELPORTE G, Olivier J, Ruffion A, Crouzet S, et al
    [Evolution of the number of incident cases, stage and first treatments for prostate cancer in France between 2001 and 2016].
    Prog Urol. 2019 Jan 8. pii: S1166-7087(18)30684.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: